Adage Capital Partners Gp, L.L.C. is the second biggest holder of Audentes Therapeutics, Inc. (BOLD)

Audentes Therapeutics, Inc. (NASDAQ:BOLD) is on recovery track with 90.37% gain from a 1-year low price of $16.55. The company lost -10.95% to attain the price of $25 on Oct. 16, 2017. Throughout the recent session, the prices were hovering between $24.98 and $24.99. These shares are 4% off its target price of $26 and the current market capitalization stands at $693.36M. The recent change has given its price a 6.55% lead over SMA 50 and -25.23% deficit over its 52-week high. The stock witnessed 0.3% gains, 21.28% gains and 64.55% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BOLD’s volatility during a week at 5.79% and during a month it has been found around 7.62%.

Audentes Therapeutics, Inc. (BOLD) Top Holders

Institutional investors currently hold around $601 million or 0% in BOLD stock. Look at its top three institutional owners. Orbimed Advisors Llc owns $134.78 million in Audentes Therapeutics, Inc., which represents roughly 19.44% of the company’s market cap and approximately 22.43% of the institutional ownership. Similar statistics are true for the second largest owner, Adage Capital Partners Gp, L.L.C., which owns 1,900,000 shares of the stock are valued at $53.33 million. The third largest holder is Versant Venture Management, Llc, which currently holds $50.72 million worth of this stock and that ownership represents nearly 7.31% of its market capitalization.

Audentes Therapeutics, Inc. 13F Filings

At the end of June reporting period, 54 institutional holders increased their position in Audentes Therapeutics, Inc. (NASDAQ:BOLD) by some 6,765,955 shares, 14 decreased positions by 1,332,530 and 8 held positions by 13,310,688. That puts total institutional holdings at 21,409,173 shares, according to SEC filings. The stock grabbed 17 new institutional investments totaling 1,127,986 shares while 5 institutional investors sold out their entire positions totaling 1,185,699 shares.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insider Trades

Multiple company employees have indulged in significant insider trading. Audentes Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President & CEO Patterson Matthew R has sold 25,000 shares of Audentes Therapeutics, Inc. (BOLD) in trading session dated Oct. 02, 2017. These shares are worth $698,000 and were traded at $27.92 each. The SEC filing shows that Orbimed Advisors Llc performed a sale of 672,000 shares. The 10% Owner disposed these shares by way of transaction on Sep. 29, 2017. The company’s shares were given away at $28.25 per share worth to an income of some $18,984,000 on account of Orbimed Advisors Llc.

Director, Lange Louis G, sold 11,000 common shares of Audentes Therapeutics, Inc. (BOLD) in the open market. In a transaction dated Sep. 29, 2017, the shares were put up for sale at an average price of $28.35, raking in a sum of $311,850. After this sale, 567,933 common shares of BOLD are directly owned by the insider, with total stake valued at $14,198,325.

In the transaction dated Sep. 27, 2017, the great number of shares disposed came courtesy the SVP, HR & Corp. Affairs; Nagler David disposed a total of 3,750 shares at an average price of $30, amounting to approximately $112,500.

Audentes Therapeutics, Inc. (BOLD) Analyst Guide

Several analysts have released their opinion on Audentes Therapeutics, Inc. (NASDAQ:BOLD), with 5 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.33 average brokerage recommendation.

Previous articleGlobalstar, Inc. (GSAT) now has -37.07 deficit over its 52-week high
Next articleBvf Inc/Il is the second biggest holder of Orexigen Therapeutics, Inc. (OREX)